Androgen Receptor Modulation Phase II, Randomized Study of MK-2206 - Bicalutamide Combination in Patients With Rising PSA at High-Risk of Progression After Primary Therapy
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 29 Apr 2018
At a glance
- Drugs MK 2206 (Primary) ; Bicalutamide
- Indications Prostate cancer
- Focus Therapeutic Use
- 02 Feb 2018 Planned primary completion date changed from 30 Nov 2017 to 30 Apr 2018.
- 16 Oct 2017 Planned primary completion date changed from 31 Aug 2017 to 30 Nov 2017.
- 10 Jun 2017 Biomarkers information updated